Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. It provides injectable collagenase under the XIAFLEX name for the treatment of Dupuytren?s contracture and Peyronie?s disease. The company also develops XIAFLEX injectable collagenase for frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroid indications, as well as for keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. The company was founded in 1957 and is headquartered in Lynbrook, New York.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||1.63||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||111.07%||Sales Growth - Q/Q||20.56%||P/E||29.54|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||17.95%||ROE||18.48%||ROI|
|Current Ratio||31.82||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.03|
|Gross Margin||Operating Margin||55.74%||Net Profit Margin||36.77%||Dividend Payout Ratio|
|Cash From Financing Activities||1.08 M||Cash From Investing Activities||-2.15 M||Cash From Operating Activities||1.99 M||Gross Profit|
|Net Profit||2.33 M||Operating Profit||3.56 M||Total Assets||34.67 M||Total Current Assets||28.99 M|
|Total Current Liabilities||910 K||Total Debt||Total Liabilities||1000 K||Total Revenue||5.61 M|
|High 52 week||71.62||Low 52 week||49.72||Last close||49.91||Last change||0.14%|
|RSI||15.08||Average true range||1.91||Beta||0.4||Volume||22.66 K|
|Simple moving average 20 days||-7.28%||Simple moving average 50 days||-10.22%||Simple moving average 200 days||-19.18%|
|Performance Week||-2.29%||Performance Month||-14.44%||Performance Quart||-20.02%||Performance Half||-24.95%|
|Performance Year||-15.05%||Performance Year-to-date||-17.64%||Volatility daily||1.2%||Volatility weekly||2.69%|
|Volatility monthly||5.52%||Volatility yearly||19.12%||Relative Volume||155.17%||Average Volume||48.38 K|
|New High||3.64%||New Low|
2019-11-14 08:53:01 | The Truth About Market Timing - November 14, 2019
2019-11-08 09:25:02 | BioSpecifics Technologies BSTC Q3 Earnings and Revenues Beat Estimates
2019-11-08 08:01:00 | BioSpecifics Reports Third Quarter 2019 Financial and Operating Results
2019-11-01 10:30:02 | BioSpecifics Technologies BSTC to Report Q3 Results: Wall Street Expects Earnings Growth
2019-10-31 14:20:34 | Here’s What Hedge Funds Think About BioSpecifics Technologies Corp. BSTC
2019-10-24 09:00:01 | The Truth About Market Timing - October 24, 2019
2019-10-21 07:17:13 | Is BioSpecifics Technologies Corp.'s NASDAQ:BSTC 20% ROE Better Than Average?
2019-10-17 09:00:01 | BioSpecifics BSTC Upgraded to Buy: Here's Why
2019-10-10 08:01:00 | BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer
2019-10-03 08:49:12 | When Does Market Timing Actually Work? - October 03, 2019
2019-09-25 14:38:57 | Have Insiders Been Selling BioSpecifics Technologies Corp. NASDAQ:BSTC Shares?
2019-09-13 08:39:12 | The Truth About Market Timing - September 13, 2019
2019-09-10 04:56:08 | Endo Files BLA for CCH With the FDA for Cellulite Candidate Revised
2019-09-09 09:50:01 | Endo International Files BLA for Label Expansion of Xiaflex
2019-08-26 08:37:12 | Yes, You Can Time the Market. Find out How - August 26, 2019
2019-08-09 17:15:09 | BioSpecifics Technologies BSTC Tops Q2 Earnings Estimates
2019-08-05 08:42:12 | Simple Market Timing Strategies That Work - August 05, 2019
2019-07-05 15:59:29 | Hedge Funds Have Never Been This Bullish On BioSpecifics Technologies Corp. BSTC
2019-05-16 16:35:08 | ImmunoGen Plunges as FDA Recommends New Study for Lead Drug
2019-05-14 14:36:06 | Catalyst CPRX Q1 Loss Narrows, Firdapse Off to a Good Start
2019-05-12 22:00:59 | Hedge Funds Have Never Been More Bullish On BioSpecifics Technologies Corp. BSTC
2019-05-10 08:26:47 | BioSpecifics: 1Q Earnings Snapshot
2019-05-02 14:34:06 | Zoetis ZTS Earnings Beat Estimates in Q1, Revenues Miss
2019-04-30 08:02:12 | What's in Store for BioSpecifics BSTC This Earnings Season?
2019-04-16 19:17:11 | Achaogen AKAO Files for Bankruptcy, Shares Plunge 65%
2019-04-12 09:45:01 | Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks
2019-04-09 10:29:02 | Zogenix Gets Refusal to File Letter From FDA for Seizure Drug
2019-04-09 10:06:02 | United Therapeutics Discontinues PAH Drug After Study Fails
2019-04-09 08:45:12 | 3 Reasons Why BioSpecifics BSTC Is a Great Growth Stock
2019-04-04 09:10:01 | 5 Stocks With Recent Price Strength Despite Market Volatility
2019-04-02 08:22:28 | BioSpecifics: 4Q Earnings Snapshot
2019-03-22 08:01:12 | 4 Top Stocks to Buy for Superb Earnings Growth
2019-03-20 09:00:01 | BioSpecifics BSTC Upgraded to Strong Buy: Here's What You Should Know
2019-03-18 08:01:00 | BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman
2019-03-05 16:36:09 | What's in Store for BioSpecifics BSTC This Earnings Season?
2019-02-21 11:27:06 | Is BioSpecifics Technologies Corp. NASDAQ:BSTC A Volatile Stock?
2019-02-04 07:35:00 | Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results
2019-01-28 09:32:02 | BioSpecifics BSTC Upgraded to Buy: Here's What You Should Know
2019-01-17 09:30:02 | Is BioSpecifics Technologies BSTC Stock Outpacing Its Medical Peers This Year?
2019-01-11 10:32:03 | Ocular OCUL Submits an sNDA for Eye Pain Drug Dextenza